Metabolic HealthTriple Hormone Agonist Retatrutide Drives 25% Weight Loss in Phase 3 Trial
Retatrutide — a once-weekly injectable that activates three hormone receptors (GIP, GLP-1, and glucagon) — was tested in a large phase 3 trial involving 2,339 adults with obesity but without diabetes. Over 80 weeks, participants receiving the highest dose lost an average of 25% of their body weight, compared to just 3.9% with placebo. Beyond weight loss, those with knee osteoarthritis reported substantially reduced pain, and those with obstructive sleep apnea saw dramatic reductions in breathing events per hour. Gastrointestinal side effects were the most common complaints. These results position retatrutide as potentially the most powerful weight-loss drug tested to date, with meaningful downstream benefits for two major obesity-related conditions that significantly affect healthspan and quality of life.
